Gpi

Investor Presentation • Nov 16, 2022

INVESTOR PRESENTATION

NOVEMBER 2022

Agenda

Group Overview

v 2022 – 2024 Strategic Business Plan Guidelines

M&A Guideline, Financial Targets & Capital Increase

VISION

To be the protagonists in the path of technological and sustainable transformation of prevention and care processes for healthcare and well-being of people

MISSION

To offer knowledge and skills for the improvement of prevention and care processes through software, services and technologies for health professionals and patients

VALUES

ETHICS

PEOPLE-CENTERED CARE

History of Growth

> 30 years of experience, management team with a track record of internal growth and M&As

International footprint

70 countries

solutions used by 2,700 customers in more than

1st player in Italy: services granting access to care

2nd player in Italy: software solutions for healthcare and social systems

integrated software, technology and service solutions to optimise the clinical, care, administrative and social processes

our work helps improve the quality of life

A History of Steady Growth FY21

70% Recurring fees € 100 m M&A deals in the last 5 years NFI 30.06.2022

€ 170.5 m

Revenue and EBITDA Breakdown H1 22

Supply Lines

main SBAs

86% of totalrevenue

Software

Care

• hospital information system
• health social care
• health administration
• blood management system
• business intelligence, data analytics
• other
• BPO health care administrative svc. (AtC,..)

• automated hospital pharmacy supply chain

• telemedicine
• other

Automation

ICT

Pay

other SBAs

14 % of totalrevenue

• HW & SW on-site / on-line maintenance and assistance
• on-site / on-line system services

• automated pharmacy warehouse

• e-payment and e-mandate solutions
• electronic storage

Group Overview

2022 – 2024 Strategic Business Plan Guidelines

M&A Guideline, Financial Targets & Capital Increase

Key Drivers of the Change in the Global Health Care Market (1/2)

Demography and socio-economic factors

Ageing population requires even more sophisticated services

Healthcare costs grow faster than economic growth

Value-based treatments are going to gain value in the US and Europe due to cost containment

Consumers expectations

Consumers wish for convenience, efficiency and personalized services

Millennials choose digital services

Consumers seek for transparency in order to compare different offers and services

Technological Environment

Accelerating technological innovations are changing people's lifestyle

Technological innovation will bring challenging changes in the healthcare industry

New technologies and platforms will see a rise in investments

Key Drivers of the Change in the Global Health Care Market (2/2)

Laws and Regulations

New regulations on interoperability

Governments' focus on improvement of cost transparency and regulationsfor cost containment

New Market Participants

Big tech companies look at the healthcare industry as a new market to get in and diversify their business

New players will invest in the market

People increasingly choose private services due to cost increase and waiting times for public healthcare services

Operational transformation

The current shortage of human resources in the healthcare industry is lifting the level of competition to attract talents

New technologies will have an extensive impact on how healthcare is delivered

Digital Health: the Solution for the Health Care Market

Shortage of medical staff (doctors, nurses)

Complex and intricate processes

Need for new forms of treatment (custom-made and remote clinical pathways)

Difficulties in capturing data in a structured and digital way

ARTIFICIAL INTELLIGENCE & DATA ANALYTICS

TELEMEDICINE

AUTOMATION

MANAGEMENT SOFTWARE

Current environment Digital health solution Effects and streamlining

Resources optimization and impact on average hospitalization

Process facilitation and consequent improvement of the patient journey

Greater integration and adoption of patient - centric operating model

Better and constant monitoring of the clinical path

Fast Growing Global and European Markets of IT Softwares and Services in Health Care

Global sales (\$ bn) European Sales (\$ bn)

2020 2021 2022 2023 2024 27.9 21.5 25.3 31.4 35.7 +12.2% +12.2%

EU

Digital Healthcare & BPO in Italy

Sources: Accenture analysis on Global Market Insights, Statista, Netconsulting cube 13

Notes: (1) Including IT Softwares and Services (excluding 5G connection); (2) Including activity monitoring, LTC monitoring, remote medication, video consultation

Potential effects of NRRP on the Italian digital healthcare market

€ 5.8 bn

2021-2026 Funds dedicated to the digitalization of healthcare of which:

• € 3.6 bn for ICT
• € 1.0 bn for telemedicine
• € 1.2 bn for medical equipment
• € 0.07 bn for cybersecurity

Competitive Ranking – Italian Top Players

Software BPO AtC (Business Process Outsourcing)

14 Sources: Accenture Notes: (1) The remaining 65% of the market includes Inhouse companies of the Italian regions and therefore is not addressable

Strategic Pillars of the Business Plan 2022 – 2024

Strategic Initiatives Sustainability, Impact, Brand and Reputation Strengthening of the ESG structure Positioning of sustainability Positioning and brand recognition Structure, Processes and Governance Agile organisation Scalability and efficiency Software Global market leader in Blood Rationalization and innovation of portfolio Increase in turnover in Italy Care & Virtual Care Consolidating BPO's position in the public and private market Become national reference operator and enabler of projects in Virtual Care Development of a telemedicine distinctive platform ICT, Automation & Pay New End-to-End Partner approach for Cybersecurity Increasing value proposition through Innovation of pharmacy & Hospital WareHouse Broadening the presence in Payment business

Strategic Pillars of the Business Plan 2022 – 2024

Strategic Initiatives

Care & Virtual Care

Strategic Initiatives

• Increasing private market share. Because of longer NHS waiting times due to the health emergency, services in private form are growing

Become national reference operator and enabler of projects in Virtual Care

Consolidate BPO's positioning

• Become a national reference operator and enabler of projects in Virtual Care by capitalizing on the competitive advantage given by PNRR funds and the Consip framework agreement
• Become a partner in the "grounding" of proximity structures (District Organization through the activation of COTs, territorial operating centers), to coordinate home services with health service

Development of telemedicine platform • Consolidate a single TELEMEDICINE E2E platform that adapts to the application context, delivering different services of patient monitoring, Patient Portal, Televisita, multi-parameter IoT, Teleconsultation, Imaging incorporating operating and healthcare centers

ICT, Automation & Pay

Strategic Initiatives

Group Overview

v 2022 – 2024 Strategic Business Plan Guidelines

M&A Guideline, Financial Targets & Capital Increase

M&A Guidelines

Become a Major European Player

expects to keep on investing in software companies both abroad and in Italy to expand the product portfolio

Focus on international software companies mainly operating in: Blood Management LIS HR /PA with an EBITDA margin > 16%

Product Portfolio Evolution:

Software Services Territories

Significant M&A Track Record

Acquisition of Tesi Group

Capital Increase for M&A and Organic Growth

25 Notes: (1) BoD called for final terms of the Offer; (2) Banca Finint, Mediocredito Trentino-Alto Adige and Seac Fin will underwrite the respective residual amount of the institutional tranche, equal to € 35 mn, in the case it will not be entirely alloted

Including Capital Increase of € 140 mn

Notes: (1) NFI includes liabilities for acquisition of equity investments (relating to earn-out mechanisms and put/call options on the percentage still held by third parties); (2) EBITDA pro forma to take into consideration a Full-Year contribution of M&A targets; Existing loan agreements and bonds could provide for a different mechanism for determining the Net Debt amount for the covenants calculation 26

Shareholder Structure and Voting Rights

Post - Capital increase Shareholder structure¹

Post - Capital increase voting rights¹

Appendix H1 22

Solid Growth H1 22

€ m	H1 22	H1 21
Revenue & other income	168.9	151.8
Adjusted Revenue1	158.1	138.1
EBITDA	17.3	14.1
EBITDA % on total revenue	10.3%	9.3%
EBITDA % on adj. revenue	11.0%	10.2%
EBIT	4.5	2.5
EBIT % on total revenue	2.7%	1.6%
EBIT % on adj. revenue	7.9%	1.8%
EBT	1.9	0.4
Net profit	0.3	0.2

Revenue € 168.9 m +11.2%

thanks to the contribution of the SBAs:

•	Other	€ 23.6 m	+20.6%
•	Care	€ 87.6 m	+9.1%
•	SW	€ 57.7 m	+11.1%	10.5% organic

EBITDA: € 17.3 m | 11.0% on adj. Revenue thanks to the contribution of the SBAs:

•	SW	€ 11.3 m	19.7%	on adj. Revenue
•	Care	€ 2.3 m	2.9%	on adj. Revenue
•	Other	€ 3.8 m	16.1.%	on Revenue

EBIT: € 4.5 m

depreciation & amortisation and provisions (€ 1.2 m)

Net Profit: € 0.3 m

net interest expenses (€ 0.5 m) > tax impact (€ 1.5 m)

Financial Highlights H1 22

€ m	30 Jun. 2022	31 Dec. 2021
Non-current assets	174.4	166.8
Net working capital	148.5	140.2
Other operating assets/(liabilities)	(54.7)	(45.3)
NET INVESTED CAPITAL	268.1	261.7
Shareholders' equity	97.6	106.2
Net Debt	170.5	155.4
TOTAL SOURCES	268.1	261.7

Non-current assets

• investments in new innovative products and solutions (developed in-house), mainly related to SBA Software
• € 5 m investment in venture capital "service tech sub-fund" of CDP venture capital sgr dedicated to investments in start-ups

Net Working Capital

inventories (€ 2,5 m), > trade receivables and contract assets (€ 7,7 m) and < trade payables (€ 1,9 m)

Shareholders' equity

(-) Dividends (€ 9.2 m)

Net Debt

Reflects the operating flows, the investments of the Group and the equity movements

Net Debt

VC € 5.0 m

1 - CONSIP Framework Agreement – Gpi Leads the Number-One Consortium*

* Gpi (ca. 37%), Accenture, Almaviva, AGFA-Gevaert, Vodafone, Iqvia Solutions Italy, Nuvyta, Kiranet, Abintrax, Biomedical Computering Systems

TELEMEDICINE & ELECTRONIC MEDICAL RECORDS

€ 900 m (D.L. 146/2021) including € 100 M of prospective extensions € 414 m for Telemedicine | € 486 m for EMR and enterprise imaging

a number of NHS entities have expressed their needs plans to start up the contracts covered by this FA.

To date (4/11/2022) requests are for the supply of a total of € 46.5 m have been received by the consortium led by Gpi. (of which ca. € 38.8 m for the EMR and ca. € 7.7 m for telemedicine software )

Further requests totalling € 63.1 m also relate to the competitive bidding procedure (among the three first-ranked consortia)

2 - CONSIP Framework Agreement – Gpi Leads the Number-One Consortium SOFTWARE for the ACCESS TO CARE

Value up to € 300 m 2 LOTS - Gpi share approx. 21%

3 - CONSIP Framework Agreement – Gpi principal in two consortia which ranked 2nd and 4th SOFTWARE for Health Care PORTALS

Value up to € 240 m 2 LOTS - Gpi share approx. 21%

Agreements terms = 18 months, extendable up to 12 more months. The single implementation contracts = max term of 48 months from the date of signing.

Software H1 22

Modular and integrated information systems:

9.7

18.7%

on adj. Revenue

on Revenue

18.6%

11.3

19.7%

19.6%

• Hospital Information System (HIS)
• Health Social Care
• Blood transfusion & tissue bank
• Business Intelligence, Data analytics

Care H1 22

Broad offer of services such as:

• Healthcare administration services
• Healthcare services (reception and diagnostic facilities)
• Telemedicine and home telecare services

91% Recurring fees 1° player ITA 4-6 years Average contract length 45% tenders win-ratio 97% Retention

Virtual Care

Other SBAs H1 22

Appendix FY21

Solid Growth FY21

€ m	FY21	FY20
Revenue & other income	326.9	271.0
Adjusted Revenue1	298.1	250.9
EBITDA	49.8	40.2
EBITDA % on total revenue	15.2%	14.8%
EBITDA % on adj. revenue	16.7%	16.0%
EBIT	23.5	19.0
EBIT % on total revenue	7.2%	7.0%
EBIT % on adj. revenue	7.9%	7.6%
EBT	16.7	13.2
Net profit	11.3	12.3

Revenue € 326.9 m +20.6% | 16.2% organic thanks to the contribution of the SBAs:

•	SW	€ 117.6 mn	+14.6%
•	Care	€166.2 mn	+25.4%
•	Other	€ 43.1 mn	+20.1%
EBITDA: € 49.8 m 16.7% on adj. Revenue
thanks to the contribution of the SBAs:

•	SW	€ 33.0 mn	28.3%	on adj. Revenue
•	Care	€ 8.8 mn	6.4%	on adj. Revenue
•	Other	€ 8.0 mn	18.7%	on total Revenue

EBIT: € 23.5 m

after depr. & amort. and provisions of € 26.3 mn

Net Profit: € 11.3 m

tax impact for € 5.4 mn – (in FY20 patent box)

Cash Dividend approved: € 0.50 p.s. payout ratio ≈81% | Date of Record 17 May 2022

Financial Highlights FY21

€ m	FY21	FY20 Restated
Non-current assets	166.8	158.4
Net working capital	140.2	109.1
Other operating assets/(liabilities)	(45.3)	(39.5)
NET INVESTED CAPITAL	261.7	227.9
Shareholders' equity	106.2	83.4
Net Debt1	155.4	144.5
TOTAL SOURCES	261.7	227.9

Non-current assets

The increase in Non-current is linked to the investments, including the acquisition of Medinfo and R&D

Net Working Capital

The increase is due to the rising amount of receivables, mainly linked to the revenues growth

Shareholders' equity

(-) Dividends (€ 7.9 m) (+) Proceedings from warrants (€ 22.3 m) (-) Related parties (€ 3.3 m minorities Riedl and Argentea)

Net Debt¹

Reflects the operating flows, the investments of the Group and the equity movements

Notes: (1) Net Debt is determined in accordance with the provisions of Guideline No. 39 issued by ESMA on 4/3/2021, and in line with the related Warning Notice No. 5/21 issued by Consob on 29/4/2021. For consistency of presentation, the corresponding value as at 31/12/2020 has also been restated. 38

Software FY21

Modular and integrated information systems:

• Hospital Information System (HIS)
• Health Social Care
• Blood transfusion & tissue bank
• Business Intelligence, Data analytics

2° player ITA

• 1-3 years Average contract length
• 50% tenders win-ratio
• 89% Retention

% on total SBA's revenue

Net of Temporary Consortia (RTI)

101.1

Care FY21

Broad offer of services such as:

• Healthcare administration services
• Healthcare services (reception and diagnostic facilities)
• Telemedicine and home telecare services
• Other

1° player ITA

4-6 years Average contract length

45% tenders win-ratio

97% Retention

% on total SBA's revenue

Net of Temporary Consortia (RTI)

91%

41

14.9

Revenue € m

FY20 FY21

17.8

3.6

Automation

Pay

2.7

ICT

AUTOMATION

Automated warehouse sales, maintenance and service fees

• Retail Pharmacies
• Hospital Pharmacies
• Wholesaler and other industries

PAY

ePayment services POS rental and related software

• Large-scale Retail
• Local PA
• Svc. providers based on POS
• System Integrator

ICT

Desktop management services fees

other system services

• Healthcare customers
• Non-healthcare PA
• Other private customers

A New Architecture of Integrated Solutions

Patients

Enabling Technologies

Disease Management

Investment Attractiveness

Leadership and Uniqueness	GPI IN THE STOCK MARKET ISIN: IT0005221517 Ticker: GPI:IM
Growth and Visibility	Price 15 Nov 2022 € Shares Ordinary	13 50 18 260 496 , ,
	Capitalisation € M	247
Technology and Service		ANALYSTS' COVERAGE – Target price
	Banca Akros	15 Sept. 2022	€ 17.50
	Intermonte SIM	26 Sept. 2022	€ 17.30
Evolution of market/NRRP	Midcap Tp Icap	3 Nov. 2022	€ 19.10

IR Contact details

Via Ragazzi del '99, 13 - 38123 Trento T +39 0461 381515 investor.relations@gpi.it

Fabrizio Redavid C. +39 335 1035499 fabrizio.redavid@gpi.it

Lorenzo Giollo

C. +39 340 8223333 lorenzo.giollo@gpi.it

Disclaimer

The material in this presentation was prepared by GPI S.p.A. ("GPI" or the "Company") without any form of independent verification; it is general, basic information about the current business of GPI as at the date of this presentation. This information is supplied in summary form and is not complete. This presentation is provided for information only and is not an offer or solicitation of an offer of purchase or sale of securities, nor shall there be any sale or purchase of securities in any jurisdiction in which such an offer, solicitation or sale should be illegal before the registration or qualification in accordance with the laws on securities of that jurisdiction. It is intended exclusively by way of a presentation to investors and is provided for information only. This presentation does not contain all information that may be relevant to an investor.

The information contained in this presentation, including the forecast financial information, must not be considered as advice or recommendations to investors or potential investors in connection with the holding, purchase or sale of securities or other products or financial instruments and does not take into account any specific investment targets nor the financial position. Before acting, it is important to consider the adequacy of information in relation to such subjects and, in particular, independent financial advice should be taken. All securities and product transactions or financial instruments entail risks, which include, amongst others, the risk of adverse or unforeseen market, financial or political developments and, in international transactions, the foreign exchange risk. The information contained in this presentation is confidential and is supplied to the user for information only and cannot be reproduced, re-sent or further distributed to anyone else, nor published, entirely or partly, for any purpose. This presentation is only distributed to and intended for: (A) persons in the European Economic Area Member States (excluding the United Kingdom), who are classed as "qualified investors" under Article 2, paragraph 1, letter e) of Directive 2003/71/EC (as amended and complete with any implementing measures applicable in each Member State); (B) in the United Kingdom, professional investment qualified investors coming under Article 19 (5) of the 2005 Order (financial promotion), the Order of Financial Services and markets and/or companies with high shareholders' equity and other persons to whom it can be lawfully disclosed, pursuant to Article 49,

paragraph 2, letters a) to d) of the Order; and (C) other persons to whom this presentation can be legally distributed and disclosed in accordance with applicable laws (all those pursuant to points (A) to (C) above, indicated as "relevant persons").

The information contained in this presentation may include forecasts. Although the Company believes it has a reasonable basis on which to make the forecasts given in this presentation, GPI warns that forecasts are no guarantee of future performance and that the effective operating results, financial conditions and conditions of liquidity and development of the segment in which GPI operates may differ considerably from those effectively achieved or suggested by the declarations given in this presentation or made by the GPI management team. Past performance is also not a reliable indication of future performance.

GPI makes no promise to update or publicly review the forecasts, even if new information is revealed or for any other reason. The information and opinions given in this presentation or in the declarations made by the GPI management team are given as at the date of this presentation or any other date, if indicated, and are subject to change without notice. Do not rely on the information given in this presentation for any purpose. No express or implicit declaration or guarantee is given by GPI, its subsidiaries or the respective consultants, functionaries, employees and agents, as regards the accuracy of information or opinions or for any loss as may derive directly or indirectly from any use of this presentation or its contents. This presentation is not intended for distribution or use by any person or entity that is a citizen or resident of a place, country or other jurisdiction in which such distribution, publication, availability or use may be in conflict with laws or regulations or which would require any registration or licence within such jurisdiction.